Edesa Biotech enters collaboration and license agreement with Kyorin Pharmaceutical for Paridiprubart in Japan

Edesa Biotech announced a collaboration and license agreement with Kyorin Pharmaceutical for Paridiprubart in Japan, valued at over $140 million with potential milestone payments.

Detected & updated continuously · Source: Nebula